Published in Curr Oncol on January 01, 2008
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation (2012) 1.14
Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci (2012) 1.08
Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol (2015) 0.95
Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol (2010) 0.84
Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol (2015) 0.83
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. Invest New Drugs (2011) 0.81
The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract (2012) 0.81
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail (2016) 0.79
Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) (2015) 0.78
Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center. Geburtshilfe Frauenheilkd (2014) 0.77
HER2-positive male breast cancer: an update. Breast Cancer (Dove Med Press) (2010) 0.76
A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) (2016) 0.75
Trastuzumab: a cardiologist's perspective. Curr Oncol (2008) 0.75
Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open (2016) 0.75
Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients. BMC Res Notes (2013) 0.75
Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study. J Cardiovasc Magn Reson (2017) 0.75
Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. Ann Transl Med (2017) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol (2007) 7.33
A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer (1973) 5.51
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta (1994) 4.92
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007) 4.19
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 2.73
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 2.72
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol (2005) 2.48
Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail (2006) 1.94
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol (2005) 1.92
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist (2006) 1.65
Clinical cardiac tolerability of trastuzumab. J Clin Oncol (2004) 1.43
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer (2007) 1.03
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol (2002) 0.98
Questions about adjuvant trastuzumab still remain. Lancet (2007) 0.92
CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry (1986) 6.14
Kin I kinesins are microtubule-destabilizing enzymes. Cell (1999) 6.07
How children and adolescents spend time across the world: work, play, and developmental opportunities. Psychol Bull (1999) 5.50
The human Arp2/3 complex is composed of evolutionarily conserved subunits and is localized to cellular regions of dynamic actin filament assembly. J Cell Biol (1997) 4.34
Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med (2010) 3.99
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer (2008) 3.39
Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A (1995) 3.28
Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem (1995) 3.08
PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol (1999) 3.05
Favorable infertility outcomes following anti-tubercular treatment prescribed on the sole basis of a positive polymerase chain reaction test for endometrial tuberculosis. Hum Reprod (2012) 2.76
Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem J (1998) 2.73
Permissive effect of the extracellular matrix on cell proliferation in vitro. Proc Natl Acad Sci U S A (1980) 2.71
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Benign intracranial hypertension. II. CSF pressure and circulation. Brain (1974) 2.69
Low fat caries. Br Dent J (1996) 2.64
Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med (1995) 2.50
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood (1999) 2.43
Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol (2001) 2.14
Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol (2001) 2.10
Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia (2001) 2.07
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev (2004) 2.05
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol (2010) 1.91
Morphological variants of plasma cell tumours. Histopathology (2004) 1.89
A survey of awareness of radiation dose among health professionals in Northern Ireland. Br J Radiol (2008) 1.80
Benign intracranial hypertension. I. Diagnosis and prognosis. Brain (1974) 1.80
Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA (1998) 1.76
XCTK2: a kinesin-related protein that promotes mitotic spindle assembly in Xenopus laevis egg extracts. J Cell Biol (1997) 1.71
Patterns of ophthalmological complaints presenting to a dedicated ophthalmic Accident & Emergency department: inappropriate use and patients' perspective. Emerg Med J (2008) 1.67
HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells. Eur J Immunol (2000) 1.64
Wellness programs: a review of the evidence. CMAJ (1998) 1.64
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat (2009) 1.63
Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) (2012) 1.62
Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer (2000) 1.61
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet (2010) 1.58
Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today (1999) 1.58
Phenotypic classes of phenoloxidase-negative mutants of the lignin-degrading fungus Phanerochaete chrysosporium. J Bacteriol (1985) 1.56
Female genital tuberculosis: early diagnosis by laparoscopy and endometrial polymerase chain reaction. Int J Tuberc Lung Dis (2010) 1.55
Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm (2003) 1.53
Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol (2012) 1.49
Functional phosphorylation sites in the C-terminal region of the multivalent multifunctional transcriptional factor CTCF. Mol Cell Biol (2001) 1.48
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 1.47
Physical education programs and exercise-induced asthma. Individualized gym programs allow asthmatic youngsters to participate with great benefit. Clin Pediatr (Phila) (1976) 1.45
Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review. Clin Oncol (R Coll Radiol) (2013) 1.45
Vanadium and diabetes. Mol Cell Biochem (1998) 1.44
Microtechniques for the automated analysis of serum total protein and albumin, urinary urea, creatinine, and hydroxyproline for nutrition surveys in developing countries. Am J Clin Nutr (1971) 1.44
Assessment of intervention outcome in the absence of baseline data: 'reconstruction' of condom use time trends using retrospective analysis of survey data. Sex Transm Infect (2010) 1.44
Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J (2000) 1.44
Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem (2000) 1.43
Antimicrobial resistance pattern and in-vitro activity of azithromycin in Salmonella isolates [corrected]. Indian J Med Microbiol (2013) 1.42
Saddle nose deformity in a patient with Crohn's disease. J Laryngol Otol (2005) 1.40
Pulse oximetry in scleroderma patients: concerns. Acta Anaesthesiol Scand (2008) 1.40
Direct surgery in the treatment of posterior communicating aneurysms. Lancet (1968) 1.39
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39
Identification and control of nosocomial adenovirus keratoconjunctivitis in an ophthalmic department. Br J Ophthalmol (2008) 1.39
An update on the careers of dentists undertaking a medical qualification. Br J Oral Maxillofac Surg (1995) 1.38
Risk factors for microbial keratitis with contemporary contact lenses: a case-control study. Ophthalmology (2008) 1.36
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis. Br J Dermatol (2011) 1.34
Distinct spatial and temporal expression patterns of K+ channel mRNAs from different subfamilies. J Neurosci (1992) 1.34
Internet usage among women with breast cancer: an exploratory study. Clin Breast Cancer (2000) 1.32
Precursors of CD3+CD4+CD8+ cells in the human thymus are defined by expression of CD34. Delineation of early events in human thymic development. J Exp Med (1993) 1.32
Antifungal activity of anthraquinone derivatives from Rheum emodi. J Ethnopharmacol (2000) 1.32
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer (2013) 1.31
Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) (2008) 1.26
Osteoarthritis. J Assoc Physicians India (2005) 1.26
Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol (1991) 1.24
Assessment of psychological distress in prospective bone marrow transplant patients. Bone Marrow Transplant (2002) 1.23
Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol (1988) 1.23
Functionally distinct subsets of human gamma/delta T cells. Eur J Immunol (1991) 1.21
Women's views on chemoprevention of breast cancer: qualitative study. Can Fam Physician (2006) 1.21
Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the blood-cerebrospinal fluid barrier. Endocrinology (2000) 1.21
Surface expression of HLA-C antigen by human extravillous trophoblast. Placenta (2000) 1.19
Quality of life in women with urinary tract infections: is benign disease a misnomer? J Am Board Fam Pract (2000) 1.18
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat (2013) 1.17
The streptococcal superantigen SMEZ exhibits wide allelic variation, mosaic structure, and significant antigenic variation. J Exp Med (2000) 1.15
Recognition of trophoblast HLA class I molecules by decidual NK cell receptors--a review. Placenta (2000) 1.15
Managing pain and comorbid depression: A public health challenge. Semin Clin Neuropsychiatry (1999) 1.15
An in vivo investigation of the structures responsible for corneal haze after photorefractive keratectomy and their effect on visual function. Ophthalmology (1996) 1.14
Temozolomide for the treatment of metastatic melanoma. Curr Oncol (2007) 1.13
Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med (1985) 1.12
Acquisition of metastatic tissue from patients with bone metastases from breast cancer. Breast Cancer Res Treat (2010) 1.12
Possible relationship between cyclic AMP and idiophasic metabolism in the white rot fungus Phanerochaete chrysosporium. J Bacteriol (1984) 1.11
Screening for undetected mental disorders in high utilizers of primary care services. J Gen Intern Med (1999) 1.09
Nucleoside transporters of mammalian cells. Pharm Biotechnol (1999) 1.09
Welding related occupational eye injuries: a narrative analysis. Inj Prev (2005) 1.08
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood (2001) 1.08
Evolution of interspersed repetitive elements inGossypium (Malvaceae). Am J Bot (1998) 1.08
Childhood antecedents of schizophrenia. BMJ (1995) 1.08
Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm (2003) 1.08
Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol (1999) 1.08
Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother (2005) 1.08
Biologically active recombinant human progastrin(6-80) contains a tightly bound calcium ion. J Biol Chem (2000) 1.08
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem (1997) 1.07
Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. Curr Oncol (2012) 1.06
mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol (2012) 1.06